| Literature DB >> 35808152 |
Jesús Gabriel González-Vega1, Juan Carlos García-Ramos2, Rocio Alejandra Chavez-Santoscoy3, Javier Emmanuel Castillo-Quiñones4, María Evarista Arellano-Garcia5, Yanis Toledano-Magaña2.
Abstract
Nanomaterials (NMs) solve specific problems with remarkable results in several industrial and scientific areas. Among NMs, silver nanoparticles (AgNPs) have been extensively employed as drug carriers, medical diagnostics, energy harvesting devices, sensors, lubricants, and bioremediation. Notably, they have shown excellent antimicrobial, anticancer, and antiviral properties in the biomedical field. The literature analysis shows a selective cytotoxic effect on cancer cells compared to healthy cells, making its potential application in cancer treatment evident, increasing the need to study the potential risk of their use to environmental and human health. A large battery of toxicity models, both in vitro and in vivo, have been established to predict the harmful effects of incorporating AgNPs in these numerous areas or those produced due to involuntary exposure. However, these models often report contradictory results due to their lack of standardization, generating controversy and slowing the advances in nanotoxicology research, fundamentally by generalizing the biological response produced by the AgNP formulations. This review summarizes the last ten years' reports concerning AgNPs' toxicity in cellular respiratory system models (e.g., mono-culture models, co-cultures, 3D cultures, ex vivo and in vivo). In turn, more complex cellular models represent in a better way the physical and chemical barriers of the body; however, results should be used carefully so as not to be misleading. The main objective of this work is to highlight current models with the highest physiological relevance, identifying the opportunity areas of lung nanotoxicology and contributing to the establishment and strengthening of specific regulations regarding health and the environment.Entities:
Keywords: 3D cultures; cell lines; co-cultures; ex vivo monocultures; in vitro; in vivo; lung toxicity; primary cultures; silver nanoparticles
Year: 2022 PMID: 35808152 PMCID: PMC9268743 DOI: 10.3390/nano12132316
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.719
Figure 1Schematic representation of AgNP formulations: uncoated (A) and with different coating agents; phytogenic (B), citrate (C), and PVP (D).
Cytotoxic effect of AgNPs in different lung cell lines.
| Coating | Size (nm) | Concentration (μg/mL) | IC50
| Exposure Time (h) | Cell Line | Outcomes | Cytotoxic Response | Ref |
|---|---|---|---|---|---|---|---|---|
| Monocultures | ||||||||
| PVP | 20 | 0, 10, 25, 50, 100 and 200 | 100 | 24, 48, 72 | A549 | Gene and protein expression decreases of p53, p21, MDM,2, and caspase 3. | Concentration-, and Time-dependency. | [ |
| PVP | 10, 20 | 5–10 | 10 nm: 56.4 | 24, 48 | A549 | Severe ADN damage. | Size-, Concentration-, and Time-dependency. | [ |
| PVP | 23 | 1–10 | NS | 24, 48, 72 | A549 | Cell cycle arrest. | Concentration-, Time-, and Cell type dependency. | [ |
| PVP | 25 | 0.4, 1, 4, 10 | >100 | 240 | NHLF | Moderate acute toxicity for MRC-5 and cellular senescence using sub-toxic concentrations associated with β-galactosidase (SA-β-gal) activity and heterochromatin foci (SAHF) | Concentration-, and Cell type-dependent. | [ |
| PVP | 50 and 200 | 5.6, 11.5, 22.5, 45 | NR | 16 | NR8383 | Increase of lactate deshydrogenase (LDH) and glucuronidase (GLU) activity. TNH-α increase at lower concentration of 50 nm citrate-AgNP and at the higher concentration of PVP-AgNP | Concentration-dependent | [ |
| Shikonin | 20 | 0.078–10 | 2.4 ± 0.11 | 24 | A549 | Cell viability and proliferation decrease. | Concentration-, and | [ |
| 10–78 | 10–100 | Wi38: 86.15 | 12, 24, 48 | A549 | Cytotoxic selective to cancer cells. | Cell-type-dependent. | [ | |
| Gallic acid | 10–30 | 5, 25, 50, 100, 200 | 46.5 | 24 | A549 | Effective in treating the radiation toxicity and resistance developed by the cancer cells during cancer treatment. | Concentration-dependent. | [ |
|
| 10–100 | 10–100 | 40,000 | 24 | A549 | Morphological damage and condensation morphology. | Concentration-dependent. | [ |
|
| 10–20 | 10–80 | 50,000 | 24 | A549 | Cancer cell growth inhibition. | Concentration-dependent. | [ |
|
| 25–50 | 25, 50, 75, 100, 150 | 100 | 12, 24, and 48 | A549 | Cell viability decrease. | Concentration-, and Time-dependent. | [ |
|
| 5, 40 | 2–10 μM | 5 nm: | 24 and 48 | A549 | Cell viability decrease. | Concentration-, and size-dependent. | [ |
|
| 10.63 | 5, 25, 50, 100 and 200 | A549: 3.6 | 24 | A549 | Cell viability decrease. | Concentration-, and Cell-Type dependent. | [ |
|
| 2–40 | 5, 10, 20, 40, 80, 160, 320 | A549: | 24 | A549 | Cell viability decreased on A549 but not on mouse embryo cells. | Concentration-, and Cell type-dependent. | [ |
| Citrate | 10, 75 | 1 | Not specified | 144 | BEAS-2B | 719 down-regulated and 998 up-regulated genes after exposure. | Concentration-, Size-dependent-, and | [ |
| Citrate | 60 | 50, 100, 200 | 200 μg Ag/mL | 24 | A549 | Lysosomal pH alkalization (dysfunction) and autophagosome formation. | Concentration-, | [ |
| Citrate, chitosan | 7–10 | 6.25 × 1012, 1.25 × 1012, 2.5 × 1012, 5 × 1012 NPs/mL | NHBE: | 0.5, 4, and 24 hours | A549. | No cytotoxicity was observed on A549 and NHBE; not responsive to Transepithelial/transendothelial electrical resistance (TEER) change. | Concentration-, | [ |
| Citrate | 10, 75 | 2 and 10 | 10 | 24 and 48 | HLF-1 | Decrease in cell viability. | Time-dependent-, | [ |
| Uncoated | 4.7, 42 | 0.84–2000 | 4.7 nm: 7700 | 24 | HbPF | Decrease in HPF viability. | Size-dependent. | [ |
|
| ||||||||
| Starch | 20 ± 4 | 7.25 μg, | Out of range | 24 | hAELVi and THP-1 | High viability. | Concentration-, | [ |
| Garcinia mangostana | 12 | 2.5 μg/mL | Out of range | 24 | A549 with BEAS-2B | Cell viability decreased for A549. | Cell type-dependent. | |
| Tannic acid | 50 ± 4 | 3 mg/L, 30 mg/L | Out of range | 24 | Calu-3, EA.hy926, and THP-1 | High toxicity at high concentration treatment. | Cell type-, and | [ |
|
| ||||||||
| Uncoated | 14 | 1.5, 4.4 and 13.2 ng/cm2. | LDH (not specified) | 6 and 24 | Organotypic-reconstituted 3D human primary small airway epithelial cell | Neutrophil accumulation. | Concentration-dependent. | [ |
| Uncoated | 20, 200 | 0.05, 0.5, 5 μg/cm2 | Out of range | 6 and 24 | 3D model representative of the alveolar barrier | ROS, cell death | Concentration-, and | [ |
| PVP | 10–20 | 40 | Out of range | 24 | 3D and 2D A549 model | Apoptosis/Necrosis | Concentration-, size-, and Model-dependent. | [ |
A549: human lung carcinoma (epithelial); BEAS-2B: human bronchial epithelium (normal); Calu-1: human lung epidermoid carcinoma (non-small-cell lung cancer); Calu-3: human lung adenocarcinoma (bronchial epithelial cells); EA.hy926: endothelial cells from the human umbilical vein; hAELVi: human alveolar epithelial cells; HLF-1: human lung fibroblast; HPF: primary cultures of pulmonary human fibroblasts; HPSAEpiC: human small airway epithelial cells; MRC-5: human fetal lung (male, normal); NCI-H 358: bronchoalveolar carcinoma (non-small-cell lung cancer); NG: natural gum; NHBE: normal human bronchial epithelial cells; NHLF: normal human lung fibroblast; NIH3T3: mouse Swiss NIH embryo (fibroblast); NS: not specified; THP-1: human acute monocytic leukemia; TKP: tamarind kernel powder; Wi38: human fetal lung (female, normal).
Figure 2The coating agent helps in modulating cytotoxic activity and antiproliferative selectivity. The image shows the trend observed for the most frequently used coating agents in AgNPs.
Observed outcomes after in vivo administration of several AgNP formulations by different administration routes.
| AgNPs Coating | Size | Dose | Time of | Model | Observed Outcome | Ref |
|---|---|---|---|---|---|---|
| PVP | 10–30 | Daily i.p. | 9 d | Male Balb/C mice | Toxic damage in major organs at all doses (lung, liver, spleen, kidney, heart, brain, and testicles) | [ |
| PVP | 25 | Final | Exposure to | Male C57BL/6 mice | Cell cycle arrest in the G2/M phase | [ |
| PVP | 50 and 200 | 3.75, 75, 150, 300 μg | 3 and 21 d | Female Wistar rat | Dose-dependent toxicity. | [ |
| PVP | 20, 60 | 10 μg | 4 and 24 h | Male ICR mouse | IL-1β and neutrophils in BALF, lung inflammation but do not indicate if PVP- or citrate-AgNps produce it. | [ |
| Citrate | 20 and | 0.5 | 24 h | Sprague Dawley Rats | Size-dependent uptake and toxicity. | [ |
| Citrate | 20 and | Single | 6 h | Male Sprague Dawley rats | Presence of silver in tissue macrophages obtained from BALF, 56 days post-exposure. | [ |
| Citrate | 20 | o.a. | 24 h | Male mice CBA/J, C57L/J, MRL/MpJ, NOD/ShiLtJ, NZB/BlNJ, NZO/HlLtJ, NZW/LacJ, PL/J, PWD/PhJ, | Strain and treatment-dependent in neutrophils in BALF with the exception of SWR/J, DBA/2J, and SM/J. | [ |
| Citrate | 20 nm | Single | 1, 3, and 5 d | Male Sprague Dawley rats | Time-dependent Ag accumulation in the lung. | [ |
| Citrate, octreotide (OCT), | 22.77 | Nebulization of | 3 d | Male and female Sprague Dawley rats | AgNPs surface modification with OCT and ALG favors AgNPs accumulation in the lung and enhances interaction with somatostatin receptors (SSRT)in tumor cell lines. | [ |
| ND | 14–15 nm | 0.05, 0.12, | 6 h/day, 5 days/week for 12 weeks | Male and female Sprague Dawley rats | Accumulation in greater quantity in the lung, and in a dose-dependent manner in the liver, kidney, blood, vessel, eye, and testicle. | [ |
| ND | 18–19 nm | 0.049, 0.133 | 6 hours/day, | Male and female Sprague Dawley rats | Accumulation in greater quantity in the lung, liver, vessel, kidney, brain, and olfactory bulb | [ |
| ND | 15 nm | 0.133 mg/m3 | Laminar horizontal | Female Fischer 344 rats | Accumulation in greater quantity in the lung, nasal cavities, lymph nodes associated with the lungs, and blood. | [ |
| ND | 18.1–19.6 nm | 0.031, 0.082, | 6 h/day, | Male Sprague Dawley rats | Accumulation in lung with a recovery of half the day after 14.7, 6.4 and 1.6 μg silver/kg dry weight of tissue in blood, followed by a low elimination phase of 60 to 100 days | [ |
| ND | 20 and | IV | 24 h, 7 and 28 d | Male Wistar rats | Time-dependent change in concentration of silver in the liver, spleen, kidneys, lungs, and the brain. | [ |
| ND | 8–22 | Daily i.p. of | 36 d | female severe combined immunodeficient (SCID) mice | Apoptosis. | [ |
| ND | 27.9–33.4 | * More information in the paper | 40 min | Rat (no defined strain or sex) | Neutrophil increase in BALF with a size and dose-dependent response. | [ |
| ND | 20 nm | i.i. | 7 and 28 d | Male Sprague Dawley rats | Lung parenchyma injury, alveolar collapse, parenchymal fibrosis. | [ |
| ND | 10–20 | i.i. 200 μg per rat | (1) Once a day for 7 days | Male Sprague Dawley rats | Enhancement of oxidative stress, mitochondrial dynamic imbalance. Thickening of the alveolar septa, accumulation of macrophages in the alveoli, formation of pulmonary bullae and pulmonary consolidation, the disintegration of the mitochondrial cristae, and swelling of the mitochondria. | [ |
BW = bodyweight; i.i. = intratracheal installation; i.p. = intraperitoneal injection; IV = intravenous injection; n.a. = nose aerosol; o.a. = oropharyngeal aspiration; * details of complete admininistration scheme could be consulted in reference [136].
Occupational exposure to different forms of silver.
| Ways of Exposure | Average Blood Levels | Study Population |
|---|---|---|
| Population in general that | 1 μg Ag/L | 26 |
| Silver material manufacturers | 0.00035 and 0.00135 mg Ag/m3, blood levels of | 2 |
| Recovery of silver from x-rays | 0.085 and 1 mg | 2 |
| Exposed to silver oxides | Media: 19.5 μg/L; range: 11–84 μg/L | 30 |
| Silver powder manufacturing | Media: 10 μg/L; range: 0.5–62 μg/L | 25 |
| Recovery of silver in waste | Media: 10 μg/L | 21 |
| Scrap silver recovery, coin | Media: 10 μg/L; range: 0.1–23 μg/L | 98 |
| Smelting, refining, and manufacturing of silver salts | Media: 11 μg/L | 37 |
| Exposed to silver aerosol | 154.4 μg/L | 1 |
Differential expression of genes in lung cell models.
| Differentially | Cellular Response | AgNP | AgNP | Cell Line | Ref |
|---|---|---|---|---|---|
| p53 ↓, p21↓, Mdm2↓, caspase-3↓ | Cell damage | 20 | PVP | A549 | [ |
| ATM protein ↑, | Cell cycle | 10, 20 | PVP | A549 | [ |
| Bax↑, Casp3↑, Casp9↑, miR-192↑, Bcl-2↓ | Cell cycle | 10.63 |
| A549 | [ |
| 685 transcripts upregulated and | Cell growth | 25 | PVP | Normal | [ |
| p53↑, p21↑, Bid↑, Bax↑, Bak ↑, Cyt C↑, Bcl-2↓, Bcl-xL↓ | Enriched signaling pathways; MAPK2, TNF, IL17, P13k-AKT, NF- Kappa B, Apoptosis | 5, 40 |
| A549 | [ |
| 719 genes were down-regulated, and 998 genes were up-regulated. | Enriched pathways related to: | 10, 75 | Citrate | BEAS-2B | [ |
| TFEB↓, LC3B-II↑, LAMP1→, P62↑, C, Bax↑, Bcl-xL↓, C, Casp3→, NF-kB↓, p53→ | Apoptosis | 10, 20 | PVP | 3D and 2D | [ |
| 493 differentially regulated transcripts | Nrf2 Regulation of | 14 | Uncoated | Organotypic-reconstituted | [ |
| HMOX-1↑, NQO1↓, SOD1↑ | Nrf2 regulates inflammatory processes | 20, 200 | Uncoated | 3D model | [ |
| Drp1↑, p-Drp1↑, Opa1↓, Mfn2↓, Casp3↑ | Fission | 10–20 | Uncoated | Sprague Dawley Rats | [ |
p53: cellular division and cellular destruction (tumor suppression); Cas-3: cell death process (apoptosis, necrosis and inflammation); Bax: anti-apoptotic regulator; BCL2: blocks apoptotic death; MMP2 (matrix metalloprotein ase-2): matrix-metallopeptidase involved in degradation of collagens (IV, V, VII, X); NQO1 (NAD(P)H dehydrogenase [quinone] 1): decodes for inducible multifunctional antioxidant enzymes; SOD1 (Superoxide dismutase 1): protein coding gene; NF-KB1 (nuclear Factor Kappa B subunit 1): DNA transcription and immune cell development; PTGS2/COX2 (prostaglandin-endoperoxide synthase 2): mediator of physiological stresses responses such as infection and inflammation; HMOX1 (heme oxygenase 1): inflammatory process and Fe homeostasis; IL6 (interleukin 6): cellular proliferation and long-term survival; Slc26a4: epithelial expressed/mucin regulation; NOTCH3: blood vessels maintenance; TGFβ1: cell growth, cell proliferation, cell differentiation, and apoptosis; sftpd: lung defense against foreign agents and toxins.
Figure 3Continuous exposure to AgNPs or silver ions generates imminent bioaccumulation in major organs, specifically in the lungs. AgNPs will interact with the different biological components existing in the lungs, facilitating the formation of protein corona and biodistribution. Once inside, AgNPs exert a cytotoxic effect through a Trojan horse-type mechanism for uncoated or non-stable coating agents or a different mechanism when the coating agent is most stable or at a high concentration. It could generate ROS overproduction, transcriptional reprogramming, and apoptosis mediated mainly by the p53 pathway. This image summarizes the proposed cytotoxic mechanism of AgNPs within the lungs.
Figure 4The image shows a proposal for a 3D model and the components that should be incorporated to generate better predictor models of the respiratory toxicity of AgNPs in vitro in future lung toxicology research. The addition of primary bronchial, epithelial, endothelial, fibroblast, ATI, and ATII cells will allow the in vitro representation of the physical barriers of the lungs. In turn, the addition of components such as pulmonary surfactant and macro-phages will allow the correct simulation of the cellular microenvironment and the immune defense system.